Semaglutide News and Research

Latest Semaglutide News and Research

New findings about nerve pathways to brown fat could lead to obesity treatments

A UCLA-led team of researchers has found nerve pathways that supply brown adipose tissue (BAT), a type of tissue that releases chemical energy from fat metabolism as heat – a finding that could pave the way toward using it to treat obesity and related metabolic conditions.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Tirzepatide is as effective at treating early-onset type 2 diabetes (T2D), a more aggressive form of the condition that normally responds less well to treatment, as it is at treating T2D diagnosed later in life, new research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has found.

4 Oct 2023

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

At this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) experts will discuss if lasting remission from diabetes is feasible in the real-world setting.

4 Oct 2023

How do different polyphenol-rich foods impact chronic diseases?

The potential of phytochemicals in promoting a healthy human diet to combat chronic disease.

27 Sep 2023

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

The complex relationship between physical activity and energy balance – food intake versus energy expenditure – is still a challenge for science, especially in light of the rising worldwide prevalence of overweight and obesity

26 Sep 2023

Research could lead to the development of new weight-loss drug that mimics exercise

A brand-new kind of drug, tested in mice, shows promising new results that could lead to the development of a new weight-loss drug that mimics exercise.

25 Sep 2023

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Meta-analysis finds tirzepatide to be the most effective GLP-1 receptor agonist for glucose and weight control in type 2 diabetes patients. The study suggests tirzepatide could be preferable in initial stages of the disease, while other GLP-1 receptor agonists combined with insulin are equally effective for long-term diabetics.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

A new meta-analysis combining 22 studies, to be presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 October), shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms of amount of body weight lost by patients.

22 Sep 2023

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

21 Sep 2023

KFF Health News' 'What the Health?': Countdown to shutdown

Health and other federal programs are at risk of shutting down, at least temporarily, as Congress races toward the Oct. 1 start of the fiscal year without having passed any of its 12 annual appropriations bills.

21 Sep 2023

KFF Health News' 'What the Health?': Underinsured is the new uninsured

The annual U.S. Census Bureau report this week revealed a drop in the uninsured rate last year as more working-age people obtained employer coverage.

14 Sep 2023

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

The study used a genome-wide association study (GWAS) to analyze random glucose levels in nearly half a million non-diabetic subjects, uncovering 150 distinct genetic signals, including 53 new ones, linked to glycemic traits and type 2 diabetes. The research also discovered a causal effect of random glucose and type 2 diabetes on lung function, identifying lung dysfunction as a new diabetes complication.

10 Sep 2023

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Groundbreaking research published today in Nature Genetics describes the largest-ever study into the genetics of random "round-the-clock" blood glucose levels.

8 Sep 2023

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

The study reveals that oral semaglutide, a medication primarily used for type 2 diabetes, effectively reduces body weight and blood glucose levels in diet-induced obese mice. The findings suggest that this drug could be a promising treatment for obesity and offer a suitable animal model for future research.

3 Sep 2023

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction.

31 Aug 2023

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children's health.

28 Aug 2023

Semaglutide could be a game-changer for patients with HFpEF and obesity

Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

25 Aug 2023

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Patients with type 2 diabetes are more than twice as likely to develop cardiovascular disease (CVD) than their healthy peers.

25 Aug 2023

Semaglutide News and Research

Latest Semaglutide News and Research

New findings about nerve pathways to brown fat could lead to obesity treatments

GLP-1 agonists linked to higher risk for gastrointestinal complications

New drug tirzepatide equally effective in early-onset and later-onset type 2 diabetes

Experts to discuss if lasting remission from diabetes is feasible in real-world setting

How do different polyphenol-rich foods impact chronic diseases?

Understanding how exercise suppresses appetite could pave the way for new obesity drugs

Research could lead to the development of new weight-loss drug that mimics exercise

Tirzepatide outshines other treatments in lowering blood sugar and weight for type 2 diabetes patients

Could metformin be a game changer for heart health in non-diabetics?

Tirzepatide superior to semaglutide for blood sugar control and body weight loss

Research reveals racial and ethnic disparities in the benefits of newer type 2 diabetes drugs

KFF Health News' 'What the Health?': Countdown to shutdown

KFF Health News' 'What the Health?': Underinsured is the new uninsured

Unlocking the genetic code of blood sugar reveals new diabetes risks and lung complications

Largest-ever study looks into the genetics of random "round-the-clock" blood glucose levels

Oral diabetes drug semaglutide fights obesity in mice: A game-changer for human treatment?

Study finds semaglutide provides benefits for patients with obesity phenotype of heart failure and HFpEF

Experts warn of unintended consequences of using GLP-1RAs to treat childhood obesity

Semaglutide could be a game-changer for patients with HFpEF and obesity

New ESC Guidelines for the management of cardiovascular disease in patients with diabetes released

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in